stockportfolio.pro
Twist Bioscience Corporation (TWST)
Healthcare · Diagnostics & Research · NasdaqGS
Twist Bioscience Corporation revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.77M | $25.43M | $54.38M | $90.10M | $132.33M | $203.56M | $245.11M | $312.97M | $376.57M |
| Gross profit | $-13.25M | $-6.76M | $6.96M | $28.69M | $51.71M | $84.23M | $89.73M | $133.35M | $191.00M |
| Net income | $-59.31M | $-71.24M | $-107.67M | $-139.93M | $-152.10M | $-217.86M | $-204.62M | $-208.73M | $-77.67M |
| Net margin | -550.8% | -280.2% | -198.0% | -155.3% | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% |
Source: Twist Bioscience Corporation SEC filings (10-K).
Explore 9 years of Twist Bioscience Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TWST in your portfolio →
Twist Bioscience Corporation financial history by metric
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Twist Bioscience Corporation — frequently asked questions
What is Twist Bioscience Corporation's revenue?
Twist Bioscience Corporation (TWST) reported revenue of $376.57M for fiscal year 2025, up 20.3% from the prior year, according to its SEC filings.
Is Twist Bioscience Corporation profitable?
No — TWST reported a net loss of $-77.67M in fiscal 2025.
What is TWST's P/E ratio?
Twist Bioscience Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Twist Bioscience Corporation growing?
TWST's revenue grew at roughly 33.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Twist Bioscience Corporation have?
As of fiscal year 2025, TWST carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Twist Bioscience Corporation's gross margin?
TWST's gross margin was 50.7% in fiscal 2025 — gross profit of $191.00M on revenue of $376.57M.
What is Twist Bioscience Corporation's market cap?
Twist Bioscience Corporation (TWST) has a market capitalization of about $4.35B, based on the latest data in our nightly-refreshed cache.
When does Twist Bioscience Corporation's fiscal year end?
TWST's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
Where does this data come from?
All figures are computed from Twist Bioscience Corporation's official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.